Clinical Trial Update: Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial investigating enoblituzumab with MGA012 or MGD013 in squamous cell carcinoma of the head and neck has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of Head and Neck

Drugs mentioned

• Enoblituzumab (enoblituzumab)
• MGA012 (MGA012)
• MGD013 (MGD013)

Snippet

Sponsor: MacroGenics | Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 2, Phase 3 | Status: WITHDRAWN